Interleukin-1 Alters Glutamate Transmission at Purkinje Cell Synapses in a Mouse Model of Multiple SclerosisGeorgia Mandolesi, Diego Centonze|Journal of Neuroscience|2013Cited by 188
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, María Trojano, Maria Pia Amato et al.|Journal of Neurology|2022Cited by 187
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Michelle Mellion et al.|The Lancet Neurology|2019Cited by 185
Epstein-Barr virus genetic variants are associated with multiple sclerosisRosella Mechelli, Giovanni Ristori, Daniela F. Angelini et al.|Neurology|2015Cited by 59
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensusDiego Centonze, Massimo Filippi, Maria A. Rocca et al.|Journal of Neurology|2021Cited by 55